A
Special Initiative
The company
is seeking individual or group investors who are interested in a
unique opportunity to improve the treatment of a disease that kills
approximately one million children under the age of five annually in
under-developed countries. Malaria is a mosquito spread disease that is readily
cured if treated early. Unfortunately, a lack of infrastructure often leads to
children not receiving care until it is too late. Researchers at the
Massachusetts General Hospital (MGH) in Boston are conducting a clinical
trial using an inhaled gas (nitric oxide) that has been shown to
significantly prolong survival in severe malaria, making treatment possible in
cases that would otherwise be hopeless. Nitric oxide gas for medical use is
too expensive for widespread use, however, and Whalen Biomedical is developing a
device to generate the gas from room air, making it available in unlimited
quantity and at low cost.
The company has just received a Phase I SBIR from the National
Institute of Allergy and Infectious Diseases (NIAID) to develop this device and
evaluate it in the treatment of malaria. We would like to accelerate this work
and contribute to lessening the impact of malaria on children in under-developed
countries.
Please contact us for more information.
|